Know Cancer

or
forgot password

The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin


N/A
N/A
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin


Inclusion Criteria:



- Cancer patients in complete remission after treatment, with serial elevation of serum
tumor markers and negative CT or other conventional imaging test.

- Patients with newly diagnosed metastatic cancer with unknown primary tumor

- Glucose levels below 150-200

- Patient signed informed consent

Exclusion Criteria:

- Pregnant or lactating women

- Patient unable or not willing to tolerate the test until its completion

- One or more of the inclusion criteria is not fulfilled

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

the impact of the imaging modality on patient management

Principal Investigator

Rachel Bar-Shalom, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rambam Health Care Campus

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

hybridCTIL

NCT ID:

NCT00396916

Start Date:

December 2004

Completion Date:

Related Keywords:

  • Cancer
  • cancer patients

Name

Location